Future research should prioritize multicenter, prospective, stratified randomized controlled trials (stratified by CKD etiology, pathology, and NLRP3 genotype) under TCMS theoretical guidance, exploring the efficacy and safety of TCMS in CKD patients and its mechanisms in regulating NLRP3 inflammasome activation. This evidence concerns the gene NLRP3 and chronic kidney disease.